Neuland Laboratories Q1 FY27 results call on Aug 5, 2026

What the company has announced

Neuland Laboratories Limited (NSE: NEULANDLAB) has scheduled its Q1 FY27 earnings conference call for August 5, 2026 at 17:30 hours IST. The company said the call will be held after the Board meeting that is set to approve the unaudited financial results for the quarter. The intimation was filed with stock exchanges on July 28, 2026 under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Regulation 30. The call is intended for investors and analysts to discuss the quarter ended June 30, 2026.

Board meeting and results timeline

The company has set August 5, 2026 as the Board meeting date to consider and approve the unaudited Q1 FY27 financial results. The same day, management is expected to discuss the results and operational updates during the earnings call. The update places Neuland in the July to August 2026 results season window referenced in the note. The trading window for the company’s equity shares was earlier stated to be closed from July 1, 2026 until 48 hours after the declaration of Q1 FY27 financial results.

How to access the earnings call

Neuland Laboratories said the call will be accessible via a webcast link with investor registration. The webcast facility referenced in the filing is a Diamond Pass webcast setup. Registration is open to institutional investors, analysts, fund managers, and other stakeholders who want to participate remotely. The company has also indicated that the call will include a management discussion followed by a Q&A session with market participants.

Investor relations contacts shared by Neuland

For coordination and queries, Neuland has provided the investor relations email: ir@neulandlabs.com. It has also listed IR representatives Runjhun Jain (98207 20993) and Minakshi Machutre (98671 44505) for investor communication support, with Ernst & Young investor relations services mentioned as support. Separately, an IR desk contact line has been cited as +91 40 6761 1600 and EY IR contact as +91 22 6192 2000 in the material provided. These details are meant to help investors with registration, access issues, and follow-up questions.

What investors are watching going into Q1 FY27

A key discussion point is how Q1 FY27 shapes up against the Q1 FY26 base that was cited at around ₹300.6 crore of total income, with EBITDA of ₹42.1 crore and PAT of ₹13.7 crore. The note also flags expectations of year-on-year growth in Q1 FY27, supported by a favourable USD/INR tailwind and a growing CMS order book, though no quantitative order book number was provided. Investors are also likely to track whether margins begin to normalise after the sharp expansion seen in Q4 FY26.

Q4 FY26 performance remains the immediate reference point

Neuland Laboratories’ latest reported quarterly numbers in the material are for Q4 FY26, when total income was stated at ₹788.7 crore versus ₹335.8 crore year-on-year. EBITDA was listed at ₹319.4 crore versus ₹58.2 crore, while PAT was ₹212.5 crore versus ₹27.7 crore. EBITDA margin expanded to 40.5% in Q4 FY26 compared with 17.3% in the year-ago period. The company’s Q1 FY27 commentary is expected to be read in the context of whether such profitability levels were one-off or repeatable.

Margin expectations and the guided band

The note states that EBITDA margins are expected to normalise towards the company’s guided sustainable band of 25% to 30%. That is a meaningful step-down from the exceptional 40.5% margin recorded in Q4 FY26. If management reiterates this band on the call, investors may focus on the drivers of margin movement such as product mix, capacity utilisation, and currency impact, within what the company chooses to disclose.

AGM schedule and proposed dividend details

Neuland has convened its 42nd Annual General Meeting for August 4, 2026 at 10:00 a.m. IST via video conferencing (VC) and other audio visual means (OAVM). The agenda includes adopting audited financial statements for FY26 and voting on a final dividend of ₹34 per equity share (340%), subject to shareholder approval. The record date cited is July 24, 2026. If approved, the dividend is payable on or after August 11, 2026.

Snapshot: key dates and numbers cited

Market snapshot and estimates referenced in the note

The material includes multiple market snapshots, including a CMP cited at ₹18,904.05 alongside a market cap of ₹24,253.69 crore, and another price point of ₹19,082 with a market capitalisation of about ₹24,354 crore. It also mentions a P/E multiple of 66.9 in the same context. Another snapshot lists price at ₹16,693, market cap at about ₹21.3K crore, and P/E ratio at 58.5, indicating the data comes from different points in time.

On estimates, the note provides a Q1 FY27 revenue range of ₹419-482 crore and PAT estimate of ₹18-23 crore, alongside a Q1 FY26 revenue base of about ₹301 crore and net profit of ₹14 crore in the preview table. These numbers are presented as a trailing-growth framework estimate rather than company guidance. Investors typically validate such expectations against management commentary on the call and the actual published results.

Why this event matters for investors

The August 5 call is a scheduled opportunity for investors to hear management’s explanation of quarter performance, especially after an unusually strong Q4 FY26 margin print and the expectation of a return to the 25% to 30% EBITDA margin band. It also sits alongside important corporate calendar events such as the AGM and the shareholder vote on the final dividend. With registration open for the webcast and IR contacts provided, the setup indicates the company is positioning for broad participation from the analyst and institutional investor community.

What to watch next

Neuland Laboratories is expected to publish its unaudited Q1 FY27 financial results after the Board meeting on August 5, 2026, followed by the 17:30 IST earnings call. Investors will watch for the company’s commentary on margins, currency impact, and business updates in the CMS and API segments as shared during the discussion. The AGM on August 4, 2026 and the dividend timeline around August 11, 2026 remain the other near-term milestones cited in the company’s disclosures.